OCCL Ltd
OCCLLTDOCCL Ltd is coiled. The quarters are improving, yet the P/E sits at the 9th percentile of its own 1-year range — the business is moving before the market.
Biggest watch item: the price is already 14 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (14 weeks in) while the P/E sits at the 9th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +207.7% year on year, and 117% of the last 2 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
OCCL Ltd trades at ₹159, in a confirmed uptrend and 14 weeks into that stage. That is +27.5% against its own 200-day average. It sits at 91% of a 52-week range of ₹93 to ₹166. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 14 straight weeks.
Today the stock is in a confirmed uptrend — week 14 of stage 2, confirmed. At ₹159 it trades +27.5% versus its 200-day average and sits at 91% of its 52-week range (₹93–₹166).
Against the market, two honest reads. Cumulative: over the last 5 months the stock moved +66% while the NIFTY 500 moved −1% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 14 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
OCCL Ltd's story is not scored yet against the markers our research file set on 14 June 2026. Where it sits in its own cycle: Not stated in the research file. Still open: If sulphur stays above ₹50/unit for 3+ quarters, margin recovery thesis fails — management has already proven wrong on this call twice.
What is proven. See the research file
What is not proven yet. If sulphur stays above ₹50/unit for 3+ quarters, margin recovery thesis fails — management has already proven wrong on this call twice.
Layer 1 read, 22 August 2026 — KEEP. One clean quarter turned this from a squeezed small-cap into the batch's best setup — but nobody from the company has explained it yet. OCCL makes insoluble sulphur for tyre makers and holds 55-58% of the Indian market. For four straight quarters its margin was pinned at 16-17% because the sulphur it buys nearly doubled in price from Rs29 to Rs52 a unit; then in June 2026 revenue jumped 79% to Rs220cr and operating margin hit 28%, with profit of Rs40cr on a normal tax rate. I checked why rather than assume: the gross margin actually got 331 basis points WORSE year on year, so the gain is unchanged fixed costs spread over far more volume on a plant that was only ~70% used — the durable kind — helped by a five-year import duty that holds the selling price up. The catch is that this is a single quarter flagged as a spike…
What would change Layer 1’s mind. The September 2026 quarter printing operating margin back at 16-18% on revenue below about Rs150cr — that would show June 2026 was a one-quarter order or pricing event rather than a new run-rate, and it would take the fixed-cost-absorption argument away entirely. Sharpened from the timeline's own falsifier ('sulphur above Rs50/unit beyond Q2 FY27 with no US tariff formalisation') and from driver D4's kill-switch, because after the June print the live question is no longer whether sulphur eases…
Layer 2 read, 22 August 2026 — BENCH. A clean profit jump is not enough while the sector is adding supply into falling margins.
What would change Layer 2’s mind. A second filed quarter that repeats the margin recovery, together with management evidence that volume and pricing rather than a one-off contract caused it, would flip BENCH to ADVANCE.
The test written in advance. A second filed quarter that repeats the margin recovery, together with management evidence that volume and pricing rather than a one-off contract caused it, would flip BENCH to ADVANCE. — the thesis as written as stated by the next result — from our Layer 2 read of 22 Aug 2026.
🚨 What the surface reading misses. The surface reading is: Input cost spike → margin compression → poor operating leverage The research reads it further: Sulphur is cyclically volatile — this is an exogenous commodity spike unrelated to OCCL's competitive position or structural margin deterioration. Sulphuric acid byproduct provides a partial natural hedge (priced at sulphur-plus). ADD prevents the full sulphur cost from being absorbed without any selling-price offset.
🚨 What the surface reading misses. The surface reading is: PE at 25th percentile of own history → cheap, buy signal The research reads it further: The 25th percentile is computed on only 4 quarterly data points (Sep 2025, Dec 2025, Mar 2026, Jun 2026) — approximately 7 months of post-demerger history. A 25th percentile on 4 data points is statistically meaningless. The more relevant read: PE at 13x vs median 13.3x means the stock is trading at approximately median valuation for its short life. EPS has been rising (500% over 8Q) but is distorted by one-off tax items.
Sources: our stock research file (14 June 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
OCCL Ltd reported ₹220 Cr of revenue in the Jun 26 quarter, +78.9% year on year. That is the 4th straight quarter of year-on-year growth. The last full year, FY26, came in at ₹506 Cr. The last four reported quarters add to ₹603 Cr.
FY26 revenue came in at ₹506 Cr (+64.8% on the year). The latest quarter (Jun 26) printed ₹220 Cr, +78.9% year on year — the 4th consecutive quarter of year-over-year growth.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
OCCL Ltd's operating margin is 28.0% in the Jun 26 quarter, +7.0 percentage points against the same quarter a year ago.
Why this happened. Sulphur averaged ₹29/unit in Jul-Sep 2025, spiked to ₹52/unit by Feb 2026 — a 79% intra-quarter surge. Each ₹1/unit move = approximately ₹1 Cr/quarter PAT impact (100,000 MT annual volume). Management noted historically such spikes are unsustainable but the Nov 2025 call was proven wrong on timing. Normalization to ₹30-35/unit would recover approximately ₹17-22 Cr annualized PAT.
The latest quarter's operating margin is 28.0%, +7.0 pp against the same quarter a year ago. Across 2 fiscal years the operating margin has ranged 17.0%–18.0%.
Why the margin moved: operating margin went +6.7 pp year on year while gross margin went −3.3 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
OCCL Ltd earned ₹40.0 Cr of net profit in the Jun 26 quarter, +207.7% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹48.0 Cr. That is 18.2% of the quarter's revenue. The same quarter a year earlier earned ₹13.0 Cr.
Jun 26 profit was ₹40.0 Cr, +207.7% year on year — the 4th consecutive quarter of growth. On the full year, FY26 printed ₹48.0 Cr (+128.6%).
Why profit moved: revenue contributed +78.9% and the margin +7.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +92.8% vs revenue +38.4%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 2 fiscal years 117% of OCCL Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹11.0 Cr of operating cash against ₹48.0 Cr of profit. After ₹12.0 Cr of capital spending, ₹−1.0 Cr was left as free cash.
FY26: operating cash of ₹11.0 Cr against reported profit of ₹48.0 Cr, leaving free cash of ₹−1.0 Cr after ₹12.0 Cr of capital spending. Across the last 2 fiscal years the conversion rate is 117% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 117%: the cash cycle tightened 32 days between FY25 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 8.3× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
OCCL Ltd's cash conversion cycle runs 160 days in FY26, down from 192 days in FY25. Capital spending ran ₹415 Cr over the last 3 years. At FY26 sales of ₹506 Cr each day of that cycle holds about ₹1.4 Cr, so roughly ₹222 Cr sits inside the business at any moment.
Why this happened. Current domestic market share 55-58%. Management targeting 60-65% by aggressively capturing share following ADD imposition. Indian tyre industry growing faster than global 2-3% demand — management cited 7-8% India growth expected for FY26. The company operates at lowest global production cost comparable to Chinese players.
FY26: debtors at 61 days, inventory at 139 days — roughly 4.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 160 days, tighter than FY25's 192.
The full loop: cash goes out to suppliers and production on day 0; stock waits 139 days to sell; customers pay about 61 days after that; and suppliers themselves are paid at 41 days — netting out to the 160-day cycle.
In money terms: at FY26 sales of ₹506 Cr, each day of the cycle holds about ₹1.4 Cr — so the 160-day loop keeps roughly ₹222 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹415 Cr over the last 3 fiscal years against ₹50.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹2.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
OCCL Ltd earns a ROCE of 13% in FY26. That is up from a trough of −86% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 9.5% net margin on 0.84× asset turns.
FY26 ROCE is 13%, recovered from a FY24 trough of −86% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 9.5% net margin × 0.84× asset turns × 1.40× balance-sheet leverage ≈ 11.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
OCCL Ltd carries ₹90.0 Cr of borrowings against ₹431 Cr of equity in FY26, a debt-to-equity of 0.21. Operating profit covers the interest bill 18×. Over 3 years borrowings went from ₹0.0 Cr to ₹90.0 Cr. Capital spending ran ₹415 Cr across the last 3 of those years.
FY26: borrowings of ₹90.0 Cr against equity of ₹431 Cr — a debt-to-equity of 0.21. Operating profit covers the interest bill 18×. Over 3 years borrowings went from ₹0.0 Cr to ₹90.0 Cr while capital spending ran ₹415 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of OCCL Ltd moved a full percentage point over the last two years — the register is quiet. Foreign institutions moved −0.7 points over the same window, to 0.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −0.9 points over 6 quarters to 4.8%; Foreign institutions: −0.7 points over 6 quarters to 0.3%; Promoters: +0.0 points over 6 quarters to 51.8%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
OCCL Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
OCCL Ltd trades at 10.4× P/E, near the bottom of its own range — cheaper only 9% of the time. Its long-run median P/E is 13.1×, measured across 1.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 10.4× is near the bottom of its own range — cheaper only 9% of the time, against a long-run median of 13.1× measured over 1.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 27 August 2026 price, OCCL Ltd was paying for profit growth of about 14.1% a year. Today the market pays 10.4× P/E, the 9th percentile of its own 1-year range.
What the two numbers say together. The multiple is low against its own past, and the growth the price is paying for is the whole of what a buyer is backing.
How to hold this number: it is a reading of one day's price, taken on 27 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
OCCL Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +64.8% | — | — | — |
| Profit | +128.6% | — | — | — |
| EPS | +122.6% | — | — | — |
4-Factor Sector Score
61.4/100 — rank 4 of 20 in Chemicals - Organic · 60% evidence confidence
OCCL Ltd scores 61.4 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 4. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 26.5 + 12.2 + 11.5 + 11.2 = 61.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What OCCL Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
US Export Operations Contradiction · 5 February 2026. In the November 2025 call, management explicitly stated they had reached an arrangement to continue selling into the US market despite the new tariffs. However, in the February 2026 call, they retrospectively stated that exports to the market were "suspended" due to the tariff, directly contradicting the prior claim of continuity. Earlier call (Nov 2025): “We have come into an arrangement where we continue to sell our products to the US. We are hopeful... this should come to a resolution soon.” Later call (Feb 2026): “Our strategy with the export market continues as before. It was suspended because of the tariff, but now that the tariffs have been rolled back, we are looking at the export market with renewed vigor.”
🚨 Sulphur Price Guidance Failure · 5 February 2026. Management guided in the November 2025 call that high sulphur prices were unsustainable and expected them to decline post-Q3 to benefit margins. In the February 2026 call, they reported that sulphur prices had actually nearly doubled (from Rs. 29 to Rs. 52) during that exact period, indicating a material failure in their input cost forecasting. Earlier call (Nov 2025): “Normally, if we look at it historically, these types of high sulphur prices are not sustainable. They do come down, and we hope that post Q3 they will come down and that should be a positive for our EBITDA margins.” Later call (Feb 2026): “The average price for July to September was about 29 rupees; the current price is about 52 rupees. There has been a substantial increase in sulfur prices.”
EBITDA Margin Guidance Retraction · 3 November 2025. Management expressed strong confidence in the July 2025 call that the then-current EBITDA margin of 21.7% was sustainable for the fiscal year. Following a sharp drop to 16.8% in the next quarter, they fully reversed this guidance in the November 2025 call, stating it is now 'very difficult' to answer questions on margins. Earlier call (Jul 2025): “Again, we feel that this is something, at least for this year, we should be having... I would say that this is a good guidance to begin with, our quarter and that is the only guidance I can give as of now.” Later call (Nov 2025): “The problem is, you know, very difficult to answer this question. Uh, you know, considering the very fluid geopolitical and geo-economical situation that we are in.”
Anti-Dumping Benefit Realization · 3 November 2025. In the July 2025 call, management confidently quantified a PBT benefit of at least INR 70-80 lakhs per month from new anti-dumping duties. However, in the November 2025 call, they stated this benefit did not materialize as guided, explaining the duties only served to 'maintain the margin in spite of the increase in raw material prices.' Earlier call (Jul 2025): “But we are looking at a benefit of about INR70 lakhs to INR80 lakhs per month... At PBT level, this is what we are looking at, at least.” Later call (Nov 2025): “So, what anti dumping duty has helped us to do is in effect maintain the margin in spite of the increase in raw material prices.”
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Valiant Organics LtdVALIANTORG | 63.2/100Mixed-positive evidence87% evidence | TURNING | 24.4/35 Revenue 1.5% · PAT 100% · OPM change 6 pp 95% evidence | 10.8/25 ROCE 5.5% · OPM 18% 95% evidence | 11.0/20 P/E 22× · PEG — 50% evidence | 17.0/20 RS sector 9.4% · RS bench 42.8% · 1Y 9.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 10.8 + 11 + 17 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Foseco India LtdFOSECOIND | 63.1/100Mixed-positive evidence87% evidence | BREAKING OUT | 19.5/35 Revenue 32.6% · PAT 20.5% · OPM change 5.2 pp 100% evidence | 16.9/25 ROCE 17.4% · OPM 23% 100% evidence | 11.5/20 P/E 44.8× · PEG 1.31 65% evidence | 15.2/20 RS sector 24.1% · RS bench 21% · 1Y -4%6 of 10 weeks ahead 70% evidence |
| Exact sum: 19.5 + 16.9 + 11.5 + 15.2 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Elantas Beck India LtdELANTAS | 62.3/100Mixed-positive evidence76% evidence | BREAKING OUT | 26.3/35 Revenue 17.6% · PAT 33.1% · OPM change 10 pp 95% evidence | 19.1/25 ROCE 21.2% · OPM 29% 76% evidence | 6.3/20 P/E 64.8× · PEG — 50% evidence | 10.6/20 RS sector -6.6% · RS bench 52.4% · 1Y 35.2%6 of 9 weeks ahead 70% evidence |
| Exact sum: 26.3 + 19.1 + 6.3 + 10.6 = 62.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 4OCCL Ltdthis pageOCCLLTD | 61.4/100Mixed-positive evidence60% evidence | BREAKING OUT | 26.5/35 Revenue 40.6% · PAT 100% · OPM change 7 pp 95% evidence | 12.2/25 ROCE 13% · OPM 28% 76% evidence | 11.5/20 P/E 10.4× · PEG — 15% evidence | 11.2/20 RS sector — · RS bench 41.5% · 1Y —9 of 9 weeks ahead 25% evidence |
| Exact sum: 26.5 + 12.2 + 11.5 + 11.2 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shri Ahimsa Naturals LtdSHRIAHIMSA | 61.0/100Thin evidence · provisional56% evidence | LEADER | 18.9/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 18.0/25 ROCE 21.7% · OPM 28% 95% evidence | 10.0/20 P/E 37.2× · PEG — 15% evidence | 14.1/20 RS sector 22.9% · RS bench 58.3% · 1Y 113%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 18 + 10 + 14.1 = 61 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Indo Amines LtdINDOAMIN | 60.6/100Mixed-positive evidence81% evidence | BASING | 22.3/35 Revenue 13.3% · PAT 24.2% · OPM change 3 pp 95% evidence | 16.8/25 ROCE 19.9% · OPM 14% 95% evidence | 14.0/20 P/E 11.3× · PEG — 50% evidence | 7.5/20 RS sector -11.9% · RS bench 4.6% · 1Y -12.6%4 of 10 weeks ahead 70% evidence |
| Exact sum: 22.3 + 16.8 + 14 + 7.5 = 60.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Balaji Amines LtdBALAMINES | 59.3/100Mixed-positive evidence82% evidence | LEADER | 26.4/35 Revenue 11.1% · PAT 41.6% · OPM change 10 pp 95% evidence | 13.3/25 ROCE 11% · OPM 25% 76% evidence | 7.0/20 P/E 36.1× · PEG — 50% evidence | 12.6/20 RS sector 18.3% · RS bench 51.3% · 1Y 53.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 13.3 + 7 + 12.6 = 59.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Nitta Gelatin India LtdNITTAGELA | 59.2/100Mixed-positive evidence72% evidence | TURNING | 18.8/35 Revenue 10.5% · PAT 24.1% · OPM change 4 pp 95% evidence | 19.1/25 ROCE 27.7% · OPM 24% 95% evidence | 9.7/20 P/E 14.4× · PEG — 50% evidence | 11.6/20 RS sector — · RS bench 46.7% · 1Y —7 of 9 weeks ahead 25% evidence |
| Exact sum: 18.8 + 19.1 + 9.7 + 11.6 = 59.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9BASF India LtdBASF | 52.7/100Mixed-positive evidence94% evidence | BREAKING OUT | 20.0/35 Revenue 6.5% · PAT 62.4% · OPM change 4 pp 100% evidence | 10.7/25 ROCE 14.5% · OPM 10% 100% evidence | 14.3/20 P/E 25.7× · PEG 1.62 100% evidence | 7.7/20 RS sector -3.3% · RS bench -3.4% · 1Y -21.2%4 of 11 weeks ahead 70% evidence |
| Exact sum: 20 + 10.7 + 14.3 + 7.7 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10GFL LtdGFLLIMITED | 51.5/100Mixed-positive evidence72% evidence | BREAKING OUT | 23.9/35 Revenue 10.5% · PAT 100% · OPM change 1064 pp 71% evidence | 7.8/25 ROCE 2.1% · OPM 28.2% 95% evidence | 11.3/20 P/E 10.6× · PEG — 15% evidence | 8.5/20 RS sector -14% · RS bench 12.9% · 1Y -2.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 7.8 + 11.3 + 8.5 = 51.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Laxmi Organic Industries LtdLXCHEM | 49.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 19.9/35 Revenue 5.5% · PAT 26% · OPM change 7.6 pp 100% evidence | 8.4/25 ROCE 4.7% · OPM 12% 100% evidence | 14.7/20 P/E 38.8× · PEG 1.14 100% evidence | 6.5/20 RS sector -19.5% · RS bench 9.7% · 1Y -16.6%9 of 10 weeks ahead 70% evidence |
| Exact sum: 19.9 + 8.4 + 14.7 + 6.5 = 49.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Fine Organic Industries LtdFINEORG | 45.6/100Mixed-negative evidence100% evidence | BREAKING OUT | 14.8/35 Revenue 7.1% · PAT 5.8% · OPM change 4 pp 100% evidence | 17.6/25 ROCE 21.5% · OPM 25% 100% evidence | 7.2/20 P/E 36.2× · PEG 2.7 100% evidence | 6.0/20 RS sector -13.8% · RS bench 12.9% · 1Y 7.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 17.6 + 7.2 + 6 = 45.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Jyoti Resins and Adhesives LtdJYOTIRES | 43.1/100Mixed-negative evidence69% evidence | 9.7/35 Revenue 12.8% · PAT -11.1% · OPM change -13 pp 95% evidence | 19.2/25 ROCE 36.5% · OPM 14% 76% evidence | 10.8/20 P/E 16.2× · PEG — 15% evidence | 3.4/20 RS sector -19.8% · RS bench -11.8% · 1Y -31.4%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 9.7 + 19.2 + 10.8 + 3.4 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Sigachi Industries LtdSIGACHI | 41.5/100Mixed-negative evidence79% evidence | BREAKING OUT | 9.0/35 Revenue -9.6% · PAT 100% · OPM change -5.2 pp 71% evidence | 7.2/25 ROCE 6.2% · OPM 13.6% 95% evidence | 8.4/20 P/E 64.5× · PEG — 50% evidence | 16.9/20 RS sector 6.2% · RS bench 38.7% · 1Y 20.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9 + 7.2 + 8.4 + 16.9 = 41.5 · Decision use: Price leads the evidence: RS versus the benchmark is 38.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Shree Ganesh Remedies LtdSGRL | 41.1/100Mixed-negative evidence76% evidence | 6.6/35 Revenue -8.8% · PAT -29.4% · OPM change -6.3 pp 95% evidence | 14.6/25 ROCE 14.1% · OPM 23.3% 76% evidence | 7.1/20 P/E 54.8× · PEG — 50% evidence | 12.8/20 RS sector 3.3% · RS bench 25.3% · 1Y 15.5%4 of 12 weeks ahead 70% evidence | |
| Exact sum: 6.6 + 14.6 + 7.1 + 12.8 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Oriental Aromatics LtdOAL | 36.0/100Mixed-negative evidence74% evidence | BREAKING OUT | 12.5/35 Revenue 13.5% · PAT -77.7% · OPM change -0.4 pp 95% evidence | 4.3/25 ROCE 4.5% · OPM 7.6% 95% evidence | 8.7/20 P/E 337× · PEG — 15% evidence | 10.5/20 RS sector -8.7% · RS bench 66.9% · 1Y 57.7%10 of 10 weeks ahead 70% evidence |
| Exact sum: 12.5 + 4.3 + 8.7 + 10.5 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Fairchem Organics LtdFAIRCHEMOR | 33.6/100Adverse evidence87% evidence | BREAKING OUT | 17.1/35 Revenue 0% · PAT 50% · OPM change 6 pp 95% evidence | 6.0/25 ROCE 3.3% · OPM 10% 95% evidence | 8.0/20 P/E 52× · PEG — 50% evidence | 2.5/20 RS sector -26.6% · RS bench -3.9% · 1Y -22.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 6 + 8 + 2.5 = 33.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Gem Aromatics LtdGEMAROMA | 24.4/100Adverse evidence65% evidence | ASLEEP | 1.8/35 Revenue -24.3% · PAT -80% · OPM change -13.6 pp 95% evidence | 6.4/25 ROCE 3.4% · OPM 3.3% 95% evidence | 8.5/20 P/E 772.2× · PEG — 15% evidence | 7.7/20 RS sector — · RS bench -10.4% · 1Y -39.3%5 of 10 weeks ahead 25% evidence |
| Exact sum: 1.8 + 6.4 + 8.5 + 7.7 = 24.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Sacheerome LtdSACHEEROME | 59.1/100Thin evidence · provisional41% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 20.3/25 ROCE 35.7% · OPM 23% 95% evidence | 9.7/20 P/E 40.1× · PEG — 15% evidence | 11.8/20 RS sector — · RS bench 46.9% · 1Y 155.5%9 of 10 weeks ahead 25% evidence |
| Exact sum: 17.3 + 20.3 + 9.7 + 11.8 = 59.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Citurgia Biochemicals LtdCITURGIA | 36.7/100Thin evidence · provisional27% evidence | 11.8/35 Revenue — · PAT -68.2% · OPM change — 33% evidence | 4.9/25 ROCE -2150% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 11.8 + 4.9 + 10 + 10 = 36.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is OCCL Ltd's share price today?
OCCL Ltd trades at ₹159. The company is valued at ₹796 Cr. The stock sits at 91% of its 52-week range of ₹93–₹166, +27.5% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 14 weeks in. — as of 11 September 2026.
What were OCCL Ltd's latest quarterly results?
OCCL Ltd reported revenue of ₹220 Cr and net profit of ₹40.0 Cr for the Jun 26 quarter. Revenue rose 78.9% and profit rose 207.7% year on year. Earnings per share were ₹8.06. The operating margin was 28.0%, 7.0 pp higher than a year earlier. — as of 11 September 2026.
What is OCCL Ltd's revenue?
OCCL Ltd reported revenue of ₹220 Cr in the Jun 26 quarter, +78.9% year on year. For the full FY26 fiscal year, revenue was ₹506 Cr (+64.8%). — as of 11 September 2026.
What is OCCL Ltd's profit?
OCCL Ltd earned ₹40.0 Cr of net profit in the Jun 26 quarter, +207.7% year on year — the 4th straight quarter of growth. Full-year FY26 profit was ₹48.0 Cr. The operating margin ran 28.0% in the latest quarter. — as of 11 September 2026.
What is OCCL Ltd's market cap?
OCCL Ltd's market capitalisation is ₹796 Cr at a share price of ₹159. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is OCCL Ltd's P/E ratio?
OCCL Ltd trades at a P/E of 10.4×, at the 9th percentile of its own 1-year range, against a long-run median of 13.1×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does OCCL Ltd pay a dividend?
Yes — OCCL Ltd's dividend payout was 29% of profit in FY26, and it recorded a payout in 2 of its last 4 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is OCCL Ltd overvalued?
On its own history, OCCL Ltd looks cheap: its P/E of 10.4× has been cheaper only 9% of the time in 1 years (long-run median 13.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is OCCL Ltd growing?
Yes — OCCL Ltd is growing: latest-quarter revenue +78.9% year on year, profit +207.7%, and the margin +7.0 pp at 28.0%. The earnings engine currently reads: improving — as of 11 September 2026.
How is OCCL Ltd performing?
OCCL Ltd is in a confirmed uptrend, 14 weeks in. Its latest quarter's revenue rose 78.9% and profit rose 207.7% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 14 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
Is OCCL Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 14 of stage 2), trading +27.5% versus its 200-day average and at 91% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is OCCL Ltd beating the market?
On recent form, yes — OCCL Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 14 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5 months the stock moved +66% against the NIFTY 500's −1% — ahead of the index over the full window. — as of 11 September 2026.
Will OCCL Ltd's share price go up?
This page publishes no price forecast for OCCL Ltd. What it measures instead: the share price is ₹159, the price is in a confirmed uptrend 14 weeks in. Its P/E of 10.4× sits at the 9th percentile of its own 1-year range. — as of 11 September 2026.
Who owns OCCL Ltd?
Promoters hold 51.8% of OCCL Ltd, foreign institutions 0.3%, domestic institutions 4.8% and the public 43.2% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does OCCL Ltd have too much debt?
No — OCCL Ltd's debt-to-equity is 0.21, and operating profit covers the interest bill 18×. FY26 borrowings were ₹90.0 Cr against equity of ₹431 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is OCCL Ltd's capex?
OCCL Ltd spent ₹415 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹12.0 Cr, with ₹2.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is OCCL Ltd's cash flow?
OCCL Ltd generated ₹11.0 Cr of operating cash flow in FY26 and ₹−1.0 Cr of free cash flow after ₹12.0 Cr of capital spending. Reported profit that year was ₹48.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is OCCL Ltd's profit real cash?
Yes — over the last 2 fiscal years, 117% of OCCL Ltd's reported profit arrived as operating cash. Though the latest year ran at 23% — the trend is the thing to watch. In FY26, operating cash was ₹11.0 Cr against reported profit of ₹48.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is OCCL Ltd in its business cycle?
OCCL Ltd's FY26 operating margin was 18.0%, against a 2-year band of 17.0%–18.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 28.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does OCCL Ltd's price assume?
At its price on 27 August 2026, OCCL Ltd was priced for profit growth of about 14.1% a year. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the OCCL Ltd story?
Biggest watch item: the price is already 14 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is OCCL Ltd a stock worth studying right now?
This is not investment advice. The machine read: OCCL Ltd is coiled. The quarters are improving, yet the P/E sits at the 9th percentile of its own 1-year range — the business is moving before the market. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!